|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.7793 - 0.8500|
|52 Week Range||0.0855 - 1.2587|
|Beta (5Y Monthly)||3.23|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER, BC / ACCESSWIRE / January 15, 2021 /Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company" or "Core One") is pleased to announce that further to its October 30, 2020 press release, the Company has completed the sale of certain of its non-core assets and subsidiaries in California for CAD$3,000,000 plus the assumption of approximately USD$4,000,000 in related liabilities.
VANCOUVER, BC / ACCESSWIRE / January 12, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (the "Company") is pleased to announce its plans to initiate another intellectual property strategy that will utilize its patented transmucosal thinstrip delivery method ("thinstrip delivery method") in combination with its proprietary biosynthetic psilocybin, developed by its wholly-owned subsidiary, Vocan Biotechnologies Inc.
VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Core One Labs Inc.